Research & Literature

Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.

Yalavarthi S, Gould TJ, Rao AN, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2015; (67(11)):2990-3003 doi:10.1002/art.39247.

Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.

Abrahams VM, Chamley LW, Salmon JE

Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(9)):1710-1721 doi:10.1002/art.40136.

The relationship between social support and health-related quality of life in patients with antiphospholipid (hughes) syndrome.

Georgopoulou S, Efraimidou S, MacLennan SJ, et al.

Modern rheumatology 2018; (28(1)):147-155 doi:10.1080/14397595.2017.1317319.

Catastrophic antiphospholipid syndrome and pregnancy. Clinical report.

Khizroeva J, Bitsadze V, Makatsariya A

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2019; (32(12)):2091-2094 doi:10.1080/14767058.2017.1422715.

Frequency of psychological alterations in primary antiphospholipid syndrome: preliminary study.

Sadetski M, Tourinho Moretto ML, Correia de Araujo RP, de Carvalho JF

Lupus 2018; (27(5)):837-840 doi:10.1177/0961203317751063.

Thrombocytopenia in high-risk patients with antiphospholipid syndrome.

Pontara E, Banzato A, Bison E, et al.

Journal of thrombosis and haemostasis : JTH 2018; (16(3)):529-532 doi:10.1111/jth.13947.

Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?

Meroni PL, Borghi MO, Grossi C, et al.

Nature reviews. Rheumatology 2018; (14(7)):433-440 doi:10.1038/s41584-018-0032-6.

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Pengo V, Denas G, Zoppellaro G, et al.

Blood 2018; (132(13)):1365-1371 doi:10.1182/blood-2018-04-848333.

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.

Belizna C, Pregnolato F, Abad S, et al.

Autoimmunity reviews 2018; (17(12)):1153-1168 doi:10.1016/j.autrev.2018.05.012.

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, et al.

RMD open 2019; (5(1)):e000924 doi:10.1136/rmdopen-2019-000924.

Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications.

Xourgia E, Tektonidou MG

Journal of autoimmunity 2019; (104()):102311 doi:10.1016/j.jaut.2019.102311.

Managing antiphospholipid syndrome in pregnancy.

Schreiber K, Hunt BJ

Thrombosis research 2019; (181 Suppl 1()):S41-S46 doi:10.1016/S0049-3848(19)30366-4.

The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome.

Chayoua W, Kelchtermans H, Gris JC, et al.

Journal of thrombosis and haemostasis : JTH 2020; (18(1)):169-179 doi:10.1111/jth.14633.

Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China.

Sun Y, Zhao J, Zhang P, et al.

Lupus 2019; (28(13)):1558-1565 doi:10.1177/0961203319882506.

Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity.

Cattini MG, Bison E, Pontara E, et al.

Journal of thrombosis and haemostasis : JTH 2020; (18(5)):1124-1132 doi:10.1111/jth.14765.

Antiphospholipid syndrome.

Petri M

Translational research : the journal of laboratory and clinical medicine 2020; (225()):70-81 doi:10.1016/j.trsl.2020.04.006.

Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature.

Urban ML, Bettiol A, Serena C, et al.

Autoimmunity reviews 2020; (19(9)):102620 doi:10.1016/j.autrev.2020.102620.

Catastrophic antiphospholipid syndrome refractory to high-dose intravenous immunoglobulin responsive to therapeutic plasma exchange.

James TE, Martin LJ, Warkentin TE, Crowther MA

Platelets 2021; (32(6)):828-831 doi:10.1080/09537104.2020.1802414.

Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.

Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, et al.

Lupus 2020; (29(12)):1556-1565 doi:10.1177/0961203320950477.

Autoimmune haemolytic anaemia and antiphospholipid antibodies in paediatrics: a systematic review and meta-analysis.

Merashli M, Arcaro A, Graf M, et al.

Clinical rheumatology 2021; (40(5)):1967-1973 doi:10.1007/s10067-020-05436-2.

Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action.

Noordermeer T, Molhoek JE, Schutgens REG, et al.

Journal of thrombosis and haemostasis : JTH 2021; (19(4)):1018-1028 doi:10.1111/jth.15241.

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.

Devreese KMJ, de Groot PG, de Laat B, et al.

Journal of thrombosis and haemostasis : JTH 2020; (18(11)):2828-2839 doi:10.1111/jth.15047.

Single or triple positivity for antiphospholipid antibodies in "carriers" or symptomatic patients: Untangling the knot.

Bertin D, Camoin-Jau L, Veit V, et al.

Journal of thrombosis and haemostasis : JTH 2021; (19(12)):3018-3030 doi:10.1111/jth.15518.

Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.

Serrano M, Espinosa G, Serrano A, Cervera R

International journal of molecular sciences 2022; (23(9)) doi:10.3390/ijms23094946.

Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis: A National Cross-Sectional Cohort Study.

Djokovic A, Stojanovich L, Stanisavljevic N, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(7)):362-366 doi:10.1097/RHU.0000000000001879.

Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.

Vandevelde A, Chayoua W, de Laat B, et al.

Journal of thrombosis and haemostasis : JTH 2022; (20(9)):2136-2150 doi:10.1111/jth.15785.

Antiphospholipid Syndrome in Patients with Venous Thromboembolism.

Pengo V, Denas G

Seminars in thrombosis and hemostasis 2023; (49(8)):833-839 doi:10.1055/s-0042-1749590.

Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.

Lee YH, Song GG

Lupus 2022; (31(11)):1335-1343 doi:10.1177/09612033221118463.

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis.

Gullapalli K, Prasad RM, Al-Abcha A, et al.

Cureus 2022; (14(9)):e29449 doi:10.7759/cureus.29449.

Platelet-derived microparticles stimulated by anti-β2GPI/β2GPI complexes induce pyroptosis of endothelial cells in antiphospholipid syndrome.

Di L, Zha C, Liu Y

Platelets 2023; (34(1)):2156492 doi:10.1080/09537104.2022.2156492.

Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients.

Stammler R, Nguyen Y, Yelnik C, et al.

Journal of thrombosis and haemostasis : JTH 2023; (21(5)):1258-1265 doi:10.1016/j.jtha.2023.02.007.

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management.

Knight JS, Branch DW, Ortel TL

BMJ (Clinical research ed.) 2023; (380()):e069717 doi:10.1136/bmj-2021-069717.

Reduced circulating Tregs and positive pANCA were robustly associated with the occurrence of antiphospholipid syndrome in patients with systemic lupus erythematosus.

Wang J, Guo HX, Cheng T, et al.

Lupus 2023; (32(6)):746-755 doi:10.1177/09612033231171287.

Antiphospholipid Syndrome: State of the Art of Clinical Management.

Depietri L, Veropalumbo MR, Leone MC, Ghirarduzzi A

Cardiovascular drugs and therapy 2025; (39(2)):385-404 doi:10.1007/s10557-023-07496-3.

Preeclampsia and the Antiphospholipid Syndrome.

Mayer-Pickel K, Nanda M, Gajic M, Cervar-Zivkovic M

Biomedicines 2023; (11(8)) doi:10.3390/biomedicines11082298.

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

Barbhaiya M, Zuily S, Naden R, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(10)):1687-1702 doi:10.1002/art.42624.

2023 ACR/EULAR antiphospholipid syndrome classification criteria.

Barbhaiya M, Zuily S, Naden R, et al.

Annals of the rheumatic diseases 2023; (82(10)):1258-1270 doi:10.1136/ard-2023-224609.

Antiphospholipid Syndrome and Kidney Involvement.

De Simone E, Sciascia S, Fenoglio R, et al.

Kidney & blood pressure research 2023; (48(1)):666-677 doi:10.1159/000529229.

Trophoblast Cell Function in the Antiphospholipid Syndrome.

Vrzić Petronijević S, Vilotić A, Bojić-Trbojević Ž, et al.

Biomedicines 2023; (11(10)) doi:10.3390/biomedicines11102681.

Embolic Phenomena of Libman-Sacks Endocarditis and Antiphospholipid Syndrome.

Gorantla A, Schaible M, Sivakumar SS, et al.

Cureus 2023; (15(10)):e46957 doi:10.7759/cureus.46957.

Performance validation of the 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria in an antiphospholipid syndrome cohort.

Zhao Y, Huang C, Zhou Y, et al.

Journal of thrombosis and haemostasis : JTH 2024; (22(6)):1660-1674 doi:10.1016/j.jtha.2024.02.019.

Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

Jacobs L, Wauters N, Lablad Y, et al.

Antibodies (Basel, Switzerland) 2024; (13(1)) doi:10.3390/antib13010021.

Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus.

Nagy N, Bói B, Papp G, et al.

Biomedicines 2024; (12(3)) doi:10.3390/biomedicines12030530.

Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?

Moyon Q, Mathian A, Papo M, et al.

Current rheumatology reports 2024; (26(7)):269-277 doi:10.1007/s11926-024-01148-7.

Pediatric catastrophic antiphospholipid syndrome with extensive skin involvement.

Pradhan S, Sinha A, Dash G, Ojha V

Pediatric dermatology 2024; (41(6)):1148-1151 doi:10.1111/pde.15642.

Antiphospholipid syndrome with major arterial thrombosis, presenting as pulmonary thromboembolism, cerebrovascular accident, and coronary artery disease: A case report and literature review.

Shirani A, Daraei M, Shirani A

Clinical case reports 2024; (12(8)):e9254 doi:10.1002/ccr3.9254.

Elucidating the Neuropsychiatric Phenomena of Antiphospholipid Syndrome in a 31-Year-Old Female.

Jamal F, Kumar R, Hakobyan N

Cureus 2024; (16(7)):e64856 doi:10.7759/cureus.64856.

TO SHOw how we have been ENgaged in the APS FiELD (What we learned on APS collaborating with Professor Yehuda Shoenfeld).

Meroni PL, Borghi MO, Raschi E, et al.

Autoimmunity reviews 2024; (23(9)):103613 doi:10.1016/j.autrev.2024.103613.

Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus.

Haladyj E, Matusiewicz A, Wysocki T, Olesinska M

Reumatologia 2024; (62(4)):266-273 doi:10.5114/reum/192028.

Diagnosis and management of antiphospholipid syndrome.

Ahn Y, Hawkins C, Pearson E, Kubler P

Australian prescriber 2024; (47(6)):179-185 doi:10.18773/austprescr.2024.055.

The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.

Zlatković-Švenda M, Rašić M, Ovuka M, et al.

Biomedicines 2025; (13(2)) doi:10.3390/biomedicines13020516.

Antiphospholipid syndrome in pregnancy: a comprehensive literature review.

Murvai VR, Galiș R, Panaitescu A, et al.

BMC pregnancy and childbirth 2025; (25(1)):337 doi:10.1186/s12884-025-07471-w.

Investigating the association between antiphospholipid syndrome and ovarian reserve: A systematic review and meta-analysis of the literature.

Hemmati N, Sahebari M, Larki M, et al.

Lupus 2025; (34(6)):588-596 doi:10.1177/09612033251332051.

Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis.

Li L, Chen J, Feng J, et al.

Frontiers in immunology 2025; (16()):1541165 doi:10.3389/fimmu.2025.1541165.

Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis.

Celia AI, Vescovo GM, Sarto G, et al.

Seminars in arthritis and rheumatism 2025; (73()):152741 doi:10.1016/j.semarthrit.2025.152741.

Impact of thromboplastin reagents on monitoring INR in a patient with triple-positive antiphospholipid syndrome: a case report.

Varju L, Bagoly Z, Ajzner É, et al.

Frontiers in immunology 2025; (16()):1591029 doi:10.3389/fimmu.2025.1591029.

Aortic mural thrombosis with bilateral renal infarction in a woman taking dienogest for adenomyosis: A case report and literature review.

Lee KY, Cheng CL, Chiang YC

Taiwanese journal of obstetrics & gynecology 2025; (64(5)):842-846 doi:10.1016/j.tjog.2024.08.015.

Left Ventricle Libman-Sacks Endocarditis Secondary to Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case Report.

Yang ZH, Gong WQ, Liu Y, Zheng MJ

The American journal of case reports 2025; (26()):e949826 doi:10.12659/AJCR.949826.

Antiphospholipid Syndrome and the Kidney.

Taghavi M, Jacobs L, Roccatello D, Sciascia S

Kidney international reports 2025; (10(11)):3757-3772 doi:10.1016/j.ekir.2025.09.010.

The influence of antiphospholipid antibodies on prothrombin time and international normalized ratio: a scoping review.

Vandevelde A, Amir M, Devreese KMJ

Critical reviews in clinical laboratory sciences 2026; (63(5)):415-432 doi:10.1080/10408363.2025.2584522.

[Clinic behavior and therapeutic status of patients with antiphospholipid syndrome].

Li Y, Liu X, Li G, et al.

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2025; (57(6)):1107-1112.

Pulmonary Embolism in Antiphospholipid Syndrome (APS)-Where Are We and Where Are We Going?

Lucki M, Grygiel-Górniak B, Lucka E, et al.

International journal of molecular sciences 2026; (27(2)) doi:10.3390/ijms27020895.

Do ethnoracial differences exist among antiphospholipid antibody-positive patients with no other systemic autoimmune diseases: results from the APS ACTION registry.

Gkrouzman E, Matijasevich A, Bonilla Richero C, et al.

Advances in rheumatology (London, England) 2026; (66(1)).

Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms.

Sevim E, Erton ZB, Erkan D

Current opinion in immunology 2026; (100()):102770 doi:10.1016/j.coi.2026.102770.